Automate Your Wheel Strategy on ABBV
With Tiblio's Option Bot, you can configure your own wheel strategy including ABBV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABBV
- Rev/Share 32.9165
- Book/Share -0.0779
- PB -2222.9401
- Debt/Equity -385.1421
- CurrentRatio 0.7358
- ROIC 0.1416
- MktCap 405548778141.0
- FreeCF/Share 10.2929
- PFCF 22.2353
- PE 107.9326
- Debt/Assets 0.5138
- DivYield 0.0286
- ROE 1.4231
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ABBV | Erste Group | Buy | Hold | -- | -- | Oct. 14, 2025 |
| Downgrade | ABBV | HSBC Securities | Buy | Hold | -- | -- | Oct. 1, 2025 |
| Upgrade | ABBV | Berenberg | Hold | Buy | -- | $270 | Sept. 17, 2025 |
| Resumed | ABBV | Piper Sandler | -- | Overweight | -- | $231 | Aug. 12, 2025 |
| Upgrade | ABBV | Daiwa Securities | Neutral | Outperform | -- | $214 | Aug. 7, 2025 |
| Downgrade | ABBV | Citigroup | Buy | Neutral | -- | $205 | May 14, 2025 |
| Initiation | ABBV | Cantor Fitzgerald | -- | Overweight | -- | $210 | April 22, 2025 |
| Resumed | ABBV | BofA Securities | -- | Neutral | -- | $191 | Dec. 10, 2024 |
| Downgrade | ABBV | Daiwa Securities | Outperform | Neutral | -- | $180 | Dec. 5, 2024 |
| Initiation | ABBV | Bernstein | -- | Market Perform | -- | $203 | Oct. 17, 2024 |
News
The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients
Published: October 21, 2025 by: PRNewsWire
Sentiment: Neutral
Each winner will be awarded a $20,000 grant to fuel their businesses. Since the program's inception, BOTOX® Cosmetic has awarded more than $1 million in grants to The Confidence Project entrepreneurs.
Read More
Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.
Read More
AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin
Published: October 17, 2025 by: PRNewsWire
Sentiment: Neutral
Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD). NORTH CHICAGO, Ill.
Read More
Can Rinvoq and Skyrizi Sales Drive Another Strong Quarter for AbbVie?
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV leans on booming Skyrizi and Rinvoq-driven sales to sustain growth and counter Humira's decline as Q3 results approach.
Read More
Final Trades: Abbvie, Amazon, Datadog and Sixth Street Specialty Lending
Published: October 13, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease
Published: October 13, 2025 by: PRNewsWire
Sentiment: Neutral
- Updated indication allows the use of RINVOQ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom use of these treatments is clinically inadvisable and who have received at least one approved systemic therapy NORTH CHICAGO, Ill. , Oct. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) approval of a supplemental new drug application (sNDA) that updates the indication statement for RINVOQ® (upadacitinib) for the treatment of adults with moderately to severely active ulcerative colitis (UC) and moderately to severely active Crohn's disease (CD).
Read More
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025?
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly's explosive GLP-1 growth and AbbVie's post-Humira rebound set up a fierce 2025 showdown between two pharma powerhouses.
Read More
My Top 5 Biotech Stocks Big Pharma Could Buy Next
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Read More
AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV shares rose 6% last week as optimism swept the pharma sector after Pfizer's landmark drug-pricing deal with the Trump administration.
Read More
AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor
Published: October 06, 2025 by: PRNewsWire
Sentiment: Neutral
OnabotulinumtoxinA (BOTOX®) met the primary endpoint in the Phase 2 trial, demonstrating a statistically significant improvement from baseline in the Tremor Disability Scale-Revised (TREDS-R) total unilateral score compared to placebo.1 The trial also met all six secondary endpoints.2 Results from safety analyses were generally consistent with the well-established safety profile of onabotulinumtoxinA.1 NORTH CHICAGO, Ill. , Oct. 6, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 2 ELATE trial evaluating the safety and efficacy of onabotulinumtoxinA (BOTOX®) compared to placebo for the treatment of upper limb essential tremor.
Read More
AbbVie: Wins Accumulating While We Wait For Next BD Steps
Published: October 03, 2025 by: Seeking Alpha
Sentiment: Positive
AbbVie is outperforming expectations with strong commercial results, pipeline progress, and the legal win that secured Rinvoq's long-term market exclusivity. ABBV has raised the full-year revenue guidance by $1.5 billion since the start of the year, and I am raising my estimate range again to reflect the better-than-expected performance. The pipeline is delivering late-stage wins, notably with Rinvoq, Epkinly, and Qulipta.
Read More
AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.
Published: September 30, 2025 by: PRNewsWire
Sentiment: Neutral
Expansion increases biologics manufacturing for immunology and oncology medicines Milestone marks progress on AbbVie's long-term commitment to U.S. manufacturing Furthers longstanding commitment to AbbVie's Massachusetts sites and workforce NORTH CHICAGO, Ill. , Sept. 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the start of construction of a $70 million expansion at its AbbVie Bioresearch Center (ABC) in Worcester, Mass.
Read More
AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options
Published: September 30, 2025 by: PRNewsWire
Sentiment: Neutral
– BLA based on data from the global Phase 1/2 CADENZA trial NORTH CHICAGO, Ill. , Sept. 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced submission of a new Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of investigational Pivekimab sunirine (PVEK) for treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Read More
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
Published: September 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
Tokyo, Japan and Cambridge and London, UK, 30 September 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a second important R&D milestone under its multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting in a payment of US$10 million to Nxera.
Read More
AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV files for FDA approval of tavapadon, a once-daily oral Parkinson's drug backed by late-stage TEMPO studies.
Read More
AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility
Published: September 29, 2025 by: PRNewsWire
Sentiment: Neutral
New state-of-the-art active pharmaceutical ingredient (API) facility will manufacture immunology, oncology and neuroscience medicines Facility expected to be fully operational and serving patients by 2027 Milestone marks progress on AbbVie's long-term commitment to U.S. manufacturing NORTH CHICAGO, Ill. , Sept. 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the start of construction of its new active pharmaceutical ingredient (API) manufacturing plant in North Chicago, Illinois.
Read More
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
AbbVie to launch ovarian cancer drug in UK at the same list price as US
Published: September 29, 2025 by: Reuters
Sentiment: Positive
AbbVie said on Monday it would launch its ovarian cancer drug Elahere in the U.K. at a list price equal to that in the U.S.
Read More
Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV eyes a 2025 rebound as Skyrizi and Rinvoq drive growth beyond Humira, with oncology and neuroscience adding momentum.
Read More
AbbVie's Rinvoq Gains Early Traction in Giant Cell Arteritis Market, Expanding Options for Rheumatologists
Published: September 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Spherix Global Insights finds majority of specialists expect Rinvoq's uptake to accelerate, with potential implications branching to the polymyalgia rheumatica landscape. Spherix Global Insights finds majority of specialists expect Rinvoq's uptake to accelerate, with potential implications branching to the polymyalgia rheumatica landscape.
Read More
Is ABBV Stock a Buy, Hold, or Sell After Its Almost 23% Rise YTD?
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie surges 22.5% YTD as new drugs Skyrizi and Rinvoq drive growth, offsetting Humira losses and fueling long-term momentum.
Read More
AbbVie Settles Rinvoq Patent Dispute: What It Means for the Stock
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Neutral
ABBV secures Rinvoq's market lead until 2037, boosting shares as strong sales and new indications fuel long-term growth prospects.
Read More
AbbVie shares rise with extension of RINVOQ patent protection to 2037
Published: September 11, 2025 by: Proactive Investors
Sentiment: Positive
Abbvie Inc (NYSE:ABBV) shares moved higher after the pharma company announced it has secured extended patent protection for its blockbuster autoimmune drug RINVOQ (upadacitinib). It said in a regulatory filing that it has reached settlements with all generic manufacturers that had filed applications to produce generic versions of RINVOQ, effectively extending US patent protection until April 2037, assuming pediatric exclusivity is granted.
Read More
AbbVie shares hit record high as key immunology drug set for exclusivity until 2037
Published: September 11, 2025 by: Reuters
Sentiment: Positive
AbbVie shares rose 4% to a record high on Thursday after the U.S. drugmaker said it expected no generic competition for its blockbuster immunology drug Rinvoq until 2037, a four-year extension, according to some analysts.
Read More
AbbVie in Settlement With Generic Drugmakers on Rinvoq
Published: September 11, 2025 by: WSJ
Sentiment: Positive
The biopharmaceutical company doesn't expect U.S. generic entry for the drug before 2037 now that it has settled litigation.
Read More
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
Published: September 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Read More
AbbVie: What's Happening With ABBV Stock?
Published: September 11, 2025 by: Forbes
Sentiment: Positive
AbbVie's stock is on the rise, and for good reason! The company just reached a major agreement with generic drug manufacturers to delay the release of a generic version of its blockbuster drug, Rinvoq, until 2037.
Read More
AbbVie Inc. (ABBV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Published: September 09, 2025 by: Seeking Alpha
Sentiment: Neutral
AbbVie Inc. (NYSE:ABBV ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:00 AM EDT Company Participants Robert Michael - CEO & Chairman of the Board Jeffrey Stewart - Executive VP & Chief Commercial Officer Roopal Thakkar - Executive VP of Research and Development & Chief Scientific Officer Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Thanks for joining us, everybody.
Read More
Calls of the Day: Abbvie, Vertex, Veeva and Vistra
Published: September 08, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee discuss the latest Calls of the Day.
Read More
About AbbVie Inc. (ABBV)
- IPO Date 2013-01-02
- Website https://www.abbvie.com
- Industry Drug Manufacturers - General
- CEO Robert A. Michael CPA
- Employees 55000